← Back to all signals
RESEARCH PAPER ANALYSIS

Effect of biologic treatments on growth in children with juvenile idiopathic arthritis: A systematic review.

AI interpretation is pending for this paper.

Open original publication →
PMID40435201
JournalPloS one
Publication Date2025-05-28
Ingested2026-08-02 12:03 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

Children with Juvenile idiopathic arthritis (JIA) often experience growth retardation due to various factors. The advent of biologic therapies has revolutionized the management of aggressive forms of JIA. This systematic review aims to provide updated insights into the impact of biologic treatments on growth retardation in pediatric JIA patients. Following PRISMA guidelines, we systematically searched Medline, Embase, and the Cochrane Library for eligible articles. Included were cohort studies, trials, and retrospective studies that evaluated growth outcomes in children with JIA receiving biologic therapy. Twelve studies published between 2003 and 2018 were analyzed, encompassing 1513 patients with a mean age of 11.4 years. Tumor necrosis factor alpha inhibitors were the predominant biologic agents used (75.8%), with a mean follow-up duration of 2 years post-biologic therapy initiation. Growth assessment criteria included Height Standard-deviation-score (HSDS), growth velocity, and height velocity (cm/year). Before biologic treatment, 15% of patients exhibited growth delay, while 75.4% had impaired growth. Following biologic therapy, growth delay decreased to 8% and impaired growth to 36.8%. Patients with systemic JIA showed lower changes in growth parameters compared to others, and no significant differences were observed between different biologic drugs. However, lower growth velocity changes were noted in patients treated with multiple biologic agents. Two studies suggested that growth catch-up was most pronounced during the first year of treatment. This systematic review highlights the potential of biologic therapies in mitigating growth impairment associated with JIA. Despite observed positive effects, further research is warranted to elucidate underlying mechanisms and optimize treatment strategies.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Predisposing, Precipitating, Perpetuating, and Protective Factors Associated With Distress in the Siblings of Children With Cancer: A Systematic Review. Journal of pediatric hematology/oncology nursing 71.4 2 Germline POT1 variants are associated with long telomeres and an unexpected broad spectrum of malignancies. Genetics in medicine open 57.0 3 Risk Factors for Pouch Neoplasia in Patients With Inflammatory Bowel Disease: A Case-Control Study. Gastro hep advances 69.0 4 Neuroblastoma Metastasis to the Mandible in Children: A Case Report and Focused Narrative Review of Reported Cases. Children (Basel, Switzerland) 57.5 5 Proteomic Profiling of Bone Marrow Aspirates from Patients with Methotrexate- and Vincristine-Resistant B-Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis. Pharmaceuticals (Basel, Switzerland) 71.7 6 A Tale of Two Cohorts: Comparing HPV Vaccination Barriers and Facilitators Among HIV-Negative and HIV-Positive Women in Tennessee. International journal of environmental research and public health 60.0 7 A Sanguinarine Analogue Targeting ROS Signaling Exhibits Anti-Tumour Effects by Inducing Apoptosis and Ferroptosis in Osteosarcoma. Antioxidants (Basel, Switzerland) 74.7 8 Prepubertal Screening for Testicular Adrenal Rest Tumors in Boys with Classic Congenital Adrenal Hyperplasia: Emerging Evidence and Practical Implications. Children (Basel, Switzerland) 57.0 9 Pharmacogenetic Predictors of Chemotherapy Treatment-Related Toxicities in Paediatric and Adolescent Acute Lymphoblastic Leukemia: A Systematic Review, Meta-Analysis and Literature-Based Candidate Prioritization. Pharmaceuticals (Basel, Switzerland) 85.98 10 [Opsoclonus Myoclonus Ataxia: Diagnostic pathway and immunosuppressive treatment in opsoclonus-myoclonus]. Medicina 68.04 11 [Sturge-Weber syndrome: comparative analysis between clinical manifestations and neuro-radiological findings]. Medicina 57.6 12 Image-Based Assessment of Anti-TNF Treatment Outcomes in Pediatric CRMO/CNO: A Single-Center Case Series. Children (Basel, Switzerland) 61.84 13 Understanding HPV Vaccine Uptake Among American Indian and Alaska Native College Students: A Scoping Review. International journal of environmental research and public health 58.7 14 Genetic Susceptibility to Anthracycline-Induced Cardiotoxicity in Australian Pediatric Cancer Patients: A Case-Control Study. JACC. Advances 54.62 15 Infection-Related Adverse Events of Tisagenlecleucel in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A FAERS Pharmacovigilance Study. Children (Basel, Switzerland) 72.16 16 Catalase Defines Radiotherapy Resistance and a Therapeutic Vulnerability in Rhabdomyosarcoma. International journal of molecular sciences 64.88 17 Multidisciplinary Management of Pediatric Craniopharyngioma: From Diagnosis to Long-Term Outcomes. Biomedicines 67.4 18 Idiopathic Syringomyelia: A Systematic Scoping Review. Journal of clinical medicine 73.5 19 Beyond Oligodendroglioma: An Integrated Diagnostic Approach to CNS Tumors with Oligodendroglioma-like Morphology, with a Focus on Morphological Pitfalls, Immunoprofiles, and Molecular Signatures. International journal of molecular sciences 56.0 20 Diagnostic Intervals in Children, Adolescents and Young Adults with Primary Bone Sarcoma: A Systematic Review. Cancers 79.6 21 Next-Generation Sequencing Refines Diagnosis and Expands Precision Medicine Opportunities in Soft Tissue Sarcomas. International journal of molecular sciences 68.64 22 Closing the evidence gap: why childhood cancer research must include fathers. Public health reviews 28.5 23 Prognostic implications of CD123 in pediatric B-cell acute lymphoblastic leukemia: a single-center retrospective analysis. Frontiers in pediatrics 79.8 24 Revisiting the hematological manifestations of vitamin B12 deficiency. Frontiers in nutrition 59.9 25 Efficacy and Safety of Adjusting Antimicrobial Therapy in Episodes of Fever and Neutropenia Catalogued as Fever of Unknown Origin in Children with Cancer: A Randomized Clinical Trial. Antibiotics (Basel, Switzerland) 76.64 26 Health Economic Assessment of PM2.5 Originating from Residential Wood Combustion-A Case Study in Northern Sweden. International journal of environmental research and public health 47.7 27 Nanotechnology in Pediatric Neurology: Applications and Innovations. Pharmaceutics 77.9 28 Disparities in Area Socioeconomic Development and Pediatric Cancer Survival in Romania-A National Pediatric Registry Study on Multiple Geographic Levels. Cancers 71.62 29 Pediatric B-Cell Acute Lymphoblastic Leukemia: Comprehensive Genomic Characterization Including SNP-Array and Analysis of Relapse Risk. Cancers 64.92 30 Precision Medicine in Dermatology: MEK Inhibition and MAPK Pathway Modulation for Congenital Melanocytic Nevi. Biomedicines 70.44 31 Pancreatoblastoma: A Descriptive and Comparative Analysis with Pancreatic Ductal Adenocarcinoma Using SEER Data. Cancers 63.1 32 Cytokines in First-Episode Psychosis: Implications for Pathophysiology: A Narrative Literature Review. Brain sciences 57.0
PATIENT-FRIENDLY SUMMARY

Effect of biologic treatments on growth in children with juvenile idiopathic arthritis: A systematic review.

For education only—not personal medical advice.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic